Overexpressed ENO1 promotes resistance to cisplatin and other anti-tumor drugs in cancer cells by increasing glycolysis and cell proliferation (Tu et al., 2010; Qian et al., 2017; Qiao et al., 2018a; Wang et al., 2019; Santana-Rivera et al., 2020), interaction with microtubules (Georges et al., 2011), and cell adhesion (Zhu et al., 2015; Principe et al., 2017). This evidence concerns the gene ENO1 and cancer.